Failure of chronic hydroxychloroquine in preventing severe complications of COVID-19 in patients with rheumatic diseases.
Identifieur interne : 000096 ( Main/Corpus ); précédent : 000095; suivant : 000097Failure of chronic hydroxychloroquine in preventing severe complications of COVID-19 in patients with rheumatic diseases.
Auteurs : Khanh Pham ; Heidi Torres ; Michael J. Satlin ; Parag Goyal ; Roy M. GulickSource :
- Rheumatology advances in practice [ 2514-1775 ] ; 2021.
Abstract
Objective
To compare baseline characteristics, clinical presentations and outcomes of patients with rheumatic conditions requiring hospitalization for coronavirus disease 2019 (COVID-19) who received chronic HCQ with those who did not receive chronic HCQ.
Methods
We identified all patients with a rheumatologic disease who were admitted with COVID-19 to two hospitals in New York City between 3 March 3 and 30 April 2020. Patients who received chronic HCQ prior to admission were matched 1:2 (±10 years of age) with patients who did not receive chronic HCQ. We compared demographics, comorbidities, HCQ dosages, concurrent medications, presentations and outcomes between the groups.
Results
There were 14 patients receiving HCQ and 28 matched control subjects. The median age of cases was 63 years [interquartile range (IQR) 43-73) and 60 years (IQR 41-75) for controls. Control subjects had a higher prevalence of pulmonary diseases (42.8%), diabetes (35.7%) and obesity (35.7%) than their case counterparts (28.6%, 14.3% and 7.1%, respectively). A higher proportion of cases than control subjects (50%
Conclusion
HCQ therapy in individuals with rheumatic conditions was not associated with less severe presentations of COVID-19 among hospitalized patients compared with individuals with rheumatic conditions not receiving HCQ.
DOI: 10.1093/rap/rkab014
PubMed: 33875975
PubMed Central: PMC7989153
Links to Exploration step
pubmed:33875975Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Failure of chronic hydroxychloroquine in preventing severe complications of COVID-19 in patients with rheumatic diseases.</title>
<author><name sortKey="Pham, Khanh" sort="Pham, Khanh" uniqKey="Pham K" first="Khanh" last="Pham">Khanh Pham</name>
<affiliation><nlm:affiliation>NewYork-Presbyterian Hospital, Weill Cornell Medical Center.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Torres, Heidi" sort="Torres, Heidi" uniqKey="Torres H" first="Heidi" last="Torres">Heidi Torres</name>
<affiliation><nlm:affiliation>NewYork-Presbyterian Hospital, Weill Cornell Medical Center.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Satlin, Michael J" sort="Satlin, Michael J" uniqKey="Satlin M" first="Michael J" last="Satlin">Michael J. Satlin</name>
<affiliation><nlm:affiliation>NewYork-Presbyterian Hospital, Weill Cornell Medical Center.</nlm:affiliation>
</affiliation>
<affiliation><nlm:affiliation>Department of Medicine, Weill Cornell Medicine, New York, NY, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Goyal, Parag" sort="Goyal, Parag" uniqKey="Goyal P" first="Parag" last="Goyal">Parag Goyal</name>
<affiliation><nlm:affiliation>NewYork-Presbyterian Hospital, Weill Cornell Medical Center.</nlm:affiliation>
</affiliation>
<affiliation><nlm:affiliation>Department of Medicine, Weill Cornell Medicine, New York, NY, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Gulick, Roy M" sort="Gulick, Roy M" uniqKey="Gulick R" first="Roy M" last="Gulick">Roy M. Gulick</name>
<affiliation><nlm:affiliation>NewYork-Presbyterian Hospital, Weill Cornell Medical Center.</nlm:affiliation>
</affiliation>
<affiliation><nlm:affiliation>Department of Medicine, Weill Cornell Medicine, New York, NY, USA.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2021">2021</date>
<idno type="RBID">pubmed:33875975</idno>
<idno type="pmid">33875975</idno>
<idno type="doi">10.1093/rap/rkab014</idno>
<idno type="pmc">PMC7989153</idno>
<idno type="wicri:Area/Main/Corpus">000096</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000096</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Failure of chronic hydroxychloroquine in preventing severe complications of COVID-19 in patients with rheumatic diseases.</title>
<author><name sortKey="Pham, Khanh" sort="Pham, Khanh" uniqKey="Pham K" first="Khanh" last="Pham">Khanh Pham</name>
<affiliation><nlm:affiliation>NewYork-Presbyterian Hospital, Weill Cornell Medical Center.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Torres, Heidi" sort="Torres, Heidi" uniqKey="Torres H" first="Heidi" last="Torres">Heidi Torres</name>
<affiliation><nlm:affiliation>NewYork-Presbyterian Hospital, Weill Cornell Medical Center.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Satlin, Michael J" sort="Satlin, Michael J" uniqKey="Satlin M" first="Michael J" last="Satlin">Michael J. Satlin</name>
<affiliation><nlm:affiliation>NewYork-Presbyterian Hospital, Weill Cornell Medical Center.</nlm:affiliation>
</affiliation>
<affiliation><nlm:affiliation>Department of Medicine, Weill Cornell Medicine, New York, NY, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Goyal, Parag" sort="Goyal, Parag" uniqKey="Goyal P" first="Parag" last="Goyal">Parag Goyal</name>
<affiliation><nlm:affiliation>NewYork-Presbyterian Hospital, Weill Cornell Medical Center.</nlm:affiliation>
</affiliation>
<affiliation><nlm:affiliation>Department of Medicine, Weill Cornell Medicine, New York, NY, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Gulick, Roy M" sort="Gulick, Roy M" uniqKey="Gulick R" first="Roy M" last="Gulick">Roy M. Gulick</name>
<affiliation><nlm:affiliation>NewYork-Presbyterian Hospital, Weill Cornell Medical Center.</nlm:affiliation>
</affiliation>
<affiliation><nlm:affiliation>Department of Medicine, Weill Cornell Medicine, New York, NY, USA.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">Rheumatology advances in practice</title>
<idno type="eISSN">2514-1775</idno>
<imprint><date when="2021" type="published">2021</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p><b>Objective</b>
</p>
<p>To compare baseline characteristics, clinical presentations and outcomes of patients with rheumatic conditions requiring hospitalization for coronavirus disease 2019 (COVID-19) who received chronic HCQ with those who did not receive chronic HCQ.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>Methods</b>
</p>
<p>We identified all patients with a rheumatologic disease who were admitted with COVID-19 to two hospitals in New York City between 3 March 3 and 30 April 2020. Patients who received chronic HCQ prior to admission were matched 1:2 (±10 years of age) with patients who did not receive chronic HCQ. We compared demographics, comorbidities, HCQ dosages, concurrent medications, presentations and outcomes between the groups.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>Results</b>
</p>
<p>There were 14 patients receiving HCQ and 28 matched control subjects. The median age of cases was 63 years [interquartile range (IQR) 43-73) and 60 years (IQR 41-75) for controls. Control subjects had a higher prevalence of pulmonary diseases (42.8%), diabetes (35.7%) and obesity (35.7%) than their case counterparts (28.6%, 14.3% and 7.1%, respectively). A higher proportion of cases than control subjects (50% </p>
</div>
<div type="abstract" xml:lang="en"><p><b>Conclusion</b>
</p>
<p>HCQ therapy in individuals with rheumatic conditions was not associated with less severe presentations of COVID-19 among hospitalized patients compared with individuals with rheumatic conditions not receiving HCQ.</p>
</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">33875975</PMID>
<DateRevised><Year>2021</Year>
<Month>04</Month>
<Day>28</Day>
</DateRevised>
<Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2514-1775</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>5</Volume>
<Issue>1</Issue>
<PubDate><Year>2021</Year>
</PubDate>
</JournalIssue>
<Title>Rheumatology advances in practice</Title>
<ISOAbbreviation>Rheumatol Adv Pract</ISOAbbreviation>
</Journal>
<ArticleTitle>Failure of chronic hydroxychloroquine in preventing severe complications of COVID-19 in patients with rheumatic diseases.</ArticleTitle>
<Pagination><MedlinePgn>rkab014</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1093/rap/rkab014</ELocationID>
<Abstract><AbstractText Label="Objective" NlmCategory="UNASSIGNED">To compare baseline characteristics, clinical presentations and outcomes of patients with rheumatic conditions requiring hospitalization for coronavirus disease 2019 (COVID-19) who received chronic HCQ with those who did not receive chronic HCQ.</AbstractText>
<AbstractText Label="Methods" NlmCategory="UNASSIGNED">We identified all patients with a rheumatologic disease who were admitted with COVID-19 to two hospitals in New York City between 3 March 3 and 30 April 2020. Patients who received chronic HCQ prior to admission were matched 1:2 (±10 years of age) with patients who did not receive chronic HCQ. We compared demographics, comorbidities, HCQ dosages, concurrent medications, presentations and outcomes between the groups.</AbstractText>
<AbstractText Label="Results" NlmCategory="UNASSIGNED">There were 14 patients receiving HCQ and 28 matched control subjects. The median age of cases was 63 years [interquartile range (IQR) 43-73) and 60 years (IQR 41-75) for controls. Control subjects had a higher prevalence of pulmonary diseases (42.8%), diabetes (35.7%) and obesity (35.7%) than their case counterparts (28.6%, 14.3% and 7.1%, respectively). A higher proportion of cases than control subjects (50% <i>vs</i>
25%) reported the use of prednisone for their rheumatic conditions prior to admission. Despite these differences in baseline characteristics, univariate logistic regression revealed no statistically significant differences in the need for mechanical ventilation [OR 1.5 (95% CI 0.34, 6.38)] or in-hospital mortality [OR 0.77 (95% CI 0.13, 4.56)].</AbstractText>
<AbstractText Label="Conclusion" NlmCategory="UNASSIGNED">HCQ therapy in individuals with rheumatic conditions was not associated with less severe presentations of COVID-19 among hospitalized patients compared with individuals with rheumatic conditions not receiving HCQ.</AbstractText>
<CopyrightInformation>© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pham</LastName>
<ForeName>Khanh</ForeName>
<Initials>K</Initials>
<Identifier Source="ORCID">https://orcid.org/0000-0002-7446-3177</Identifier>
<AffiliationInfo><Affiliation>NewYork-Presbyterian Hospital, Weill Cornell Medical Center.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Torres</LastName>
<ForeName>Heidi</ForeName>
<Initials>H</Initials>
<AffiliationInfo><Affiliation>NewYork-Presbyterian Hospital, Weill Cornell Medical Center.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Satlin</LastName>
<ForeName>Michael J</ForeName>
<Initials>MJ</Initials>
<AffiliationInfo><Affiliation>NewYork-Presbyterian Hospital, Weill Cornell Medical Center.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Department of Medicine, Weill Cornell Medicine, New York, NY, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Goyal</LastName>
<ForeName>Parag</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>NewYork-Presbyterian Hospital, Weill Cornell Medical Center.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Department of Medicine, Weill Cornell Medicine, New York, NY, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Gulick</LastName>
<ForeName>Roy M</ForeName>
<Initials>RM</Initials>
<AffiliationInfo><Affiliation>NewYork-Presbyterian Hospital, Weill Cornell Medical Center.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Department of Medicine, Weill Cornell Medicine, New York, NY, USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2021</Year>
<Month>03</Month>
<Day>02</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>Rheumatol Adv Pract</MedlineTA>
<NlmUniqueID>101736676</NlmUniqueID>
<ISSNLinking>2514-1775</ISSNLinking>
</MedlineJournalInfo>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword>
<Keyword MajorTopicYN="N">hydroxychloroquine</Keyword>
<Keyword MajorTopicYN="N">lupus</Keyword>
<Keyword MajorTopicYN="N">pre-exposure prophylaxis</Keyword>
<Keyword MajorTopicYN="N">preventive</Keyword>
<Keyword MajorTopicYN="N">rheumatoid arthritis</Keyword>
<Keyword MajorTopicYN="N">rheumatologic diseases</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>11</Month>
<Day>10</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2021</Year>
<Month>02</Month>
<Day>01</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2021</Year>
<Month>4</Month>
<Day>20</Day>
<Hour>6</Hour>
<Minute>34</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2021</Year>
<Month>4</Month>
<Day>21</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2021</Year>
<Month>4</Month>
<Day>21</Day>
<Hour>6</Hour>
<Minute>1</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">33875975</ArticleId>
<ArticleId IdType="doi">10.1093/rap/rkab014</ArticleId>
<ArticleId IdType="pii">rkab014</ArticleId>
<ArticleId IdType="pmc">PMC7989153</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>BMJ. 2020 May 14;369:m1849</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32409561</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2020 Dec 1;324(21):2165-2176</Citation>
<ArticleIdList><ArticleId IdType="pubmed">33165621</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2020 Jul 28;71(15):732-739</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32150618</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Rheumatol. 2020 Sep;2(9):e557-e564</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32838309</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Jun 11;382(24):2372-2374</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32302078</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Nov 19;383(21):2030-2040</Citation>
<ArticleIdList><ArticleId IdType="pubmed">33031652</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Rheum Dis. 2020 May 31;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32475831</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Rheum Dis. 2020 Jul;79(7):859-866</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32471903</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA Intern Med. 2020 Jul 1;180(7):934-943</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32167524</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Nov 19;383(21):2041-2052</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32706953</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Rheumatol. 2021 Jan;3(1):e19-e27</Citation>
<ArticleIdList><ArticleId IdType="pubmed">33349815</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Rheum Dis. 2020 Aug 5;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32759263</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Discov. 2020 Mar 18;6:16</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32194981</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2020 Jul 16;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32674126</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2021 Feb 4;384(5):403-416</Citation>
<ArticleIdList><ArticleId IdType="pubmed">33378609</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Infect Dis. 2020 May;20(5):533-534</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32087114</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Open Forum Infect Dis. 2020 Sep 23;7(10):ofaa446</Citation>
<ArticleIdList><ArticleId IdType="pubmed">33134417</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA Intern Med. 2021 Feb 1;181(2):195-202</Citation>
<ArticleIdList><ArticleId IdType="pubmed">33001138</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Jul 2;383(1):85-88</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32348641</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000096 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000096 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= CovidChloroV1 |flux= Main |étape= Corpus |type= RBID |clé= pubmed:33875975 |texte= Failure of chronic hydroxychloroquine in preventing severe complications of COVID-19 in patients with rheumatic diseases. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:33875975" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a CovidChloroV1
![]() | This area was generated with Dilib version V0.6.38. | ![]() |